12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Belinostat: Additional Phase II data

Additional data from the open-label, international Phase II PXD101-CLN-17 in 89 patients with previously untreated CUP showed that belinostat plus carboplatin and paclitaxel produced a median OS of 11.5 months vs. 9.1 months for carboplatin and paclitaxel. Spectrum previously reported that belinostat plus chemotherapy non-significantly improved OS vs. chemotherapy (p=0.2906). Belinostat also missed the primary endpoint of PFS vs. chemotherapy alone (5.4 vs. 5.3 months, p=0.5526),...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >